Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries

NEXT STORY
Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer
PREV STORY
CB2 Insights Expands Clinical Division into New Jersey with the Asset Acquisition of New Jersey Alternative Medicine Clinics
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

author_avatar
NASDAQ Market News

Seventy-one scholars from 13 countries attended the 27th International Science Conference

author_avatar
NASDAQ Market News

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

author_avatar
NASDAQ Market News